Scarica l'app Stockscreener
0.7628
0.79%
0.0064
Precedente Chiudi:
$0.7564
Aprire:
$0.7954
Volume 24 ore:
28.42M
Relative Volume:
1.19
Capitalizzazione di mercato:
$142.65M
Reddito:
$424.90K
Utile/perdita netta:
$-94.02M
Rapporto P/E:
-0.3071
EPS:
-2.4842
Flusso di cassa netto:
$-51.25M
1 W Prestazione:
-33.70%
1M Prestazione:
-45.15%
6M Prestazione:
+80.54%
1 anno Prestazione:
-67.42%
Intervallo 1D:
$0.7325
$0.7975
Intervallo di 1 settimana:
$0.712
$1.18
Portata 52W:
$0.1611
$3.39
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Nome
Outlook Therapeutics Inc
Settore
Industria
Telefono
(609) 619-3990
Indirizzo
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
0.7629 | 141.44M | 424.90K | -94.02M | -51.25M | -2.4842 |
VRTX
Vertex Pharmaceuticals Inc
|
514.14 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
811.04 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
994.68 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.54 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
359.54 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-08-28 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-12-02 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2024-02-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-12-27 | Aggiornamento | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-08-30 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | Downgrade | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-07-13 | Iniziato | CapitalOne | Overweight |
| 2023-04-03 | Iniziato | Guggenheim | Buy |
| 2023-02-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-10-31 | Iniziato | BTIG Research | Buy |
| 2022-09-13 | Iniziato | Chardan Capital Markets | Buy |
| 2019-09-11 | Iniziato | Ladenburg Thalmann | Buy |
| 2019-05-16 | Iniziato | Oppenheimer | Outperform |
| 2019-04-22 | Iniziato | Ascendiant Capital Markets | Buy |
Mostra tutto
Outlook Therapeutics Inc Borsa (OTLK) Ultime notizie
OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp - Zacks Investment Research
Outlook Therapeutics Insider Bought Shares Worth $2,499,999, According to a Recent SEC Filing - Moomoo
Outlook Therapeutics Posts Q3 Financials, Raises Funds for Lytenava Launch - VisionMonday.com
Outlook Therapeutics Inc (OTLK) Stock News Today - TradingKey
symbol__ Stock Quote Price and Forecast - cnn.com
MSN Money - MSN
OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal - Stocktwits
Outlook Therapeutics CEO Robert Jahr acquires shares and warrants for $0 - Investing.com South Africa
OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision - Stocktwits
Outlook Therapeutics (OTLK) Stock May Be No Bargain With Approval But Weak Balance Sheet - Yahoo Finance
Outlook Therapeutics CFO Kenyon acquires 101,010 shares By Investing.com - Investing.com South Africa
Outlook Therapeutics (OTLK) CEO purchases 151,515 shares and matching warrants - Stock Titan
Outlook Therapeutics, Inc. 2026 Q3ResultsEarnings Call Presentation (NASDAQ:OTLK) 2026-08-14 - Seeking Alpha
Outlook Therapeutics director Ghiath Sukhtian buys $2.5m in shares By Investing.com - Investing.com Australia
Outlook Therapeutics director Ghiath Sukhtian buys $2.5m in shares - Investing.com
Outlook Therapeutics CFO Kenyon acquires 101,010 shares - Investing.com
Outlook Therapeutics (OTLK) investor GMS Ventures reports 16.4% beneficial stake - Stock Titan
Outlook Therapeutics (OTLK) insider-linked entity buys 2.5M shares plus 2.5M warrants - Stock Titan
Outlook Therapeutics (OTLK) CFO Lawrence Kenyon buys 101K shares plus 101K warrants - Stock Titan
Outlook Therapeutics(OTLK) Stock Options Chain | Quotes & News - Moomoo
OTLK Q3 FY2026 earnings call - finance.biggo.com
Outlook Therapeutics to Report Q3 After $55 Million Stock Sale Sends Shares Tumbling - finance.biggo.com
Friday's session: most active stocks - ChartMill
OTLK Reiterated by BTIG -- Price Target Maintained at $4.00 - GuruFocus
Oncobiologics Q3 Earnings Call Highlights - MarketBeat
Earnings call transcript: Outlook Therapeutics narrows loss in Q3 2026 as launch nears - Investing.com
Outlook Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
OTLK: FDA-approved LYTENAVA targets rapid U.S. launch and $500M+ peak sales by 2030 - TradingView
Outlook Therapeutics Announces $55 Million Equity Offering - TipRanks
Transcript: Outlook Therapeutics Q3 2026 Earnings Conference Call - Benzinga
Outlook Therapeutics, Inc. (OTLK) Stock Forecasts - Yahoo! Finance Canada
Outlook Therapeutics (OTLK) Q3 Earnings Miss Highlight Valuation Challenges - GuruFocus
Q3 2026 Outlook Therapeutics Inc Earnings Call Transcript - GuruFocus
Form 8K OUTLOOK THERAPEUTICS INC For: 14 August By Investing.com - Investing.com Nigeria
Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Outlook Therapeutics reports Q3 FY2026 net loss $20.3M, adjusted loss $10.9M; readies U.S. launch of LYTENAVA - TradingView
Outlook Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026 - marketscreener.com
Outlook Therapeutics reports Q3 loss, targets late 2026 launch By Investing.com - Investing.com Nigeria
Outlook Therapeutics reports Q3 loss, targets late 2026 launch - Investing.com
Outlook Therapeutics Q3 net loss narrows slightly as costs drop - TradingView
FDA-approved LYTENAVA targets wet AMD; U.S. launch planned by year-end 2026 - Stock Titan
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 - GlobeNewswire
Outlook Therapeutics Q3 Results: Loss narrows to 8 cents per share - scanx.trade
Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most - Benzinga
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants - mx.advfn.com
These 3 Stocks Led Wall Street’s Biggest Gains On Tuesday – Here’s Why - stocktwits.com
Outlook Therapeutics (OTLK) Stock Forum and Discussion - Moomoo
Outlook Therapeutics faces financial challenges ahead of Q3 earnings with expected loss and recent stock offering. - Pluang
Outlook Therapeutics (OTLK) Q3 Earnings Preview: Valuation Chall - GuruFocus
Outlook Therapeutics' $55 Million Rescue: A Dilution Trade-Off on the Road to LYTENAVA's US Launch - AD HOC NEWS
Why is Outlook Therapeutics stock plunging today? By Investing.com - Investing.com South Africa
Outlook Therapeutics Inc Azioni (OTLK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Outlook Therapeutics Inc Azioni (OTLK) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sukhtian Faisal Ghiath | Director |
Jul 29 '26 |
Buy |
1.05 |
95,398 |
99,996 |
220,972 |
| Haddadin Yezan Munther | Director |
Jun 02 '26 |
Buy |
0.83 |
29,000 |
24,145 |
66,167 |
| Sukhtian Ghiath M. | Director |
May 28 '26 |
Buy |
0.59 |
8,539,709 |
5,000,000 |
22,092,068 |
| Sukhtian Faisal Ghiath | Director |
May 27 '26 |
Buy |
0.41 |
122,174 |
50,006 |
125,574 |
| Haddadin Yezan Munther | Director |
May 26 '26 |
Buy |
0.44 |
34,000 |
14,960 |
37,167 |
| THURMAN RANDY H | Director |
May 26 '26 |
Buy |
0.43 |
5,000 |
2,145 |
5,593 |
| HILZINGER KURT J | Director |
May 26 '26 |
Buy |
0.44 |
400,000 |
176,520 |
423,655 |
2.16%
1.18%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):